Pediatric formulation development - Challenges of today and strategies for tomorrow: Summary report from M-CERSI workshop 2019.


Journal

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
ISSN: 1873-3441
Titre abrégé: Eur J Pharm Biopharm
Pays: Netherlands
ID NLM: 9109778

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 18 07 2020
revised: 04 11 2020
accepted: 12 04 2021
pubmed: 21 4 2021
medline: 20 11 2021
entrez: 20 4 2021
Statut: ppublish

Résumé

A workshop on "Pediatric Formulation Development: Challenges of Today and Strategies for Tomorrow" was organized jointly by the University of Maryland's Center of Excellence in Regulatory Science and Innovation (M-CERSI), the U.S. Food and Drug Administration (FDA) and the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Drug Product Pediatric Working Group (PWG). This multi-disciplinary, pediatric focused workshop was held over a two-day period (18-19 Jun 2019) and consisted of participants from industry, regulatory agencies, academia and other organizations from both US and Europe. The workshop consisted of sequential sessions on formulation, analytical, clinical, and regulatory and industry lessons learned and future landscape. Each session began with a series of short framing presentations, followed by facilitated breakout sessions and panel discussion. The formulation session was dedicated to three main topics pertaining to drug product acceptability, excipients in pediatrics and oral administration device considerations. The analytical session discussed key considerations for dosing vehicle selection and analytical strategies for testing of different dosage forms, specifically mini-tablets (multiparticulates). The clinical session highlighted the influence of pediatric pharmacokinetics prediction on formulation design, pediatric drug development strategies and clinical considerations to support pediatric formulation design. The regulatory and industry lessons learned and future landscape session explored the regional differences that exist in regulatory expectations, requirements for pediatric formulation development, and key patient-centric factors to consider when developing novel pediatric formulations. This session also discussed potential collaboration opportunities and tools for pediatric formulation development. This manuscript summarizes the key discussions and outcomes of all the sessions in the workshop with a broadened review and discussion of the topics that were covered.

Identifiants

pubmed: 33878432
pii: S0939-6411(21)00102-8
doi: 10.1016/j.ejpb.2021.04.011
pii:
doi:

Substances chimiques

Excipients 0
Pharmaceutical Preparations 0
Tablets 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

54-65

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

David Cheng Thiam Tan (DCT)

AbbVie Inc., North Chicago, IL, United States. Electronic address: cheng.tan@abbvie.com.

Yuet Mei Khong (YM)

AbbVie Inc., North Chicago, IL, United States.

Steven Mount (S)

Astra Zeneca, Macclesfield, United Kingdom.

Elizabeth Galella (E)

Bristol-Myers Squibb, New Brunswick, NJ, United States.

Biplob Mitra (B)

Bristol-Myers Squibb, Summit, NJ, United States.

Stuart Charlton (S)

Bristol-Myers Squibb, Moreton, CH46 1QW, United Kingdom.

Maren Kuhli (M)

Daiichi Sankyo Europe GmbH, 85276 Pfaffenhofen, Germany.

Robert Ternik (R)

Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States.

Jennifer Walsh (J)

Jenny Walsh Consulting Ltd, BioCity Nottingham, NG1 1GF, United Kingdom.

Asha Rajapakshe (A)

Merck & Co Inc., West Point, PA, United States.

Karen Thompson (K)

Merck & Co Inc., West Point, PA, United States.

Shailly Mehrotra (S)

Otsuka Pharmaceutical Development & Commercialization, Princeton, NJ, United States.

Matthew Santangelo (M)

Pfizer Inc., Groton, CT, United States.

Jing Liu (J)

Pfizer Inc., Groton, CT, United States.

Trupti Dixit (T)

Pfizer Inc., Lake Forest, IL, United States.

Daniel Schaufelberger (D)

Schaufelberger Consulting LLC, NJ, United States.

Shahla Jamzad (S)

Sunovion Pharmaceuticals, Marlborough, MA, United States.

Sandra Klein (S)

University of Greifswald, Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology, Greifswald, Germany.

Stephen W Hoag (SW)

University of Maryland, School of Pharmacy, Baltimore, MD, United States.

Jian Wang (J)

U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States.

Elimika Pfuma Fletcher (EP)

U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States.

Mona Khurana (M)

U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States.

John Alexander (J)

U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States.

Erica Radden (E)

U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States.

Ramesh Sood (R)

U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States.

Arzu Selen (A)

U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States. Electronic address: arzu.Selen@fda.hhs.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH